IMiDs and BET inhibitors target distinct pathways of MYC dysregulation by super-enhancers in multiple myeloma

被引：1

作者：

Riggs, Daniel L. ^{[1
]}

Herzog, Camille ^{[2
]}

Garbitt, Victoria M. ^{[1
]}

Keane, Niamh ^{[3
]}

Hillukka, Courtney J. ^{[1
]}

Hammond, Zachary J. ^{[1
]}

Wiedmeier, Julia E. ^{[1
]}

Welsh, Seth J. ^{[1
]}

Tian, Shulan ^{[4
]}

Yan, Huihuang ^{[4
]}

Maity, Ranjan ^{[5
]}

Bahlis, Nizar ^{[5
]}

Neri, Paola ^{[5
]}

Kuehl, W. Michael ^{[6
]}

Chesi, Marta ^{[1
]}

Bergsagel, P. Leif ^{[1
]}

机构：

[1] Mayo Clin Arizona, Scottsdale, AZ USA

[2] Harvard Sch Dent Med, Boston, MA USA

[3] Univ Ireland, Galway, Ireland

[4] Mayo Clin Rochester, Rochester, MN USA

[5] Univ Calgary, Calgary, AB, Canada

[6] NCI, Bethesda, MD 20892 USA

来源：

CANCER RESEARCH | 2019年 / 79卷 / 13期

关键词：

D O I：

10.1158/1538-7445.SABCS18-3015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3015

引用

页数：2

共 7 条

[1] Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma
M Affer
M Chesi
W D Chen
J J Keats
Y N Demchenko
K Tamizhmani
V M Garbitt
D L Riggs
L A Brents
A V Roschke
S Van Wier
R Fonseca
P L Bergsagel
W M Kuehl
Leukemia, 2014, 28 : 1725 - 1735
[2] Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma
Affer, M.
Chesi, M.
Chen, W. D.
Keats, J. J.
Demchenko, Y. N.
Tamizhmani, K.
Garbitt, V. M.
Riggs, D. L.
Brents, L. A.
Roschke, A. V.
Van Wier, S.
Fonseca, R.
Bergsagel, P. L.
Kuehl, W. M.
LEUKEMIA, 2014, 28 (08) : 1725 - 1735
[3] Disrupting Ectopic Super-Enhancers to Treat Multiple Myeloma
Welsh, Seth
Riggs, Daniel
Meermeier, Erin
Shi, Chang-Xin
Garbitt, Victoria
Sharik, Meaghen E.
Du, Megan
Todd, Kennedi
Hammond, Zachary
Brown, Sochilt
Stein, Caleb K.
Neri, Paola
Bahlis, Nizar J.
Barwick, Benjamin G.
Boise, Larry H.
Kuehl, W. Michael
Chesi, Marta
Bergsagel, P. Leif
BLOOD, 2021, 138
[4] Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors
Andricovich, Jaclyn
Perkail, Stephanie
Kai, Yan
Casasanta, Nicole
Peng, Weiqun
Tzatsos, Alexandros
CANCER CELL, 2018, 33 (03) : 512 - +
[5] The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors
Abruzzese, Maria Pia
Bilotta, Maria Teresa
Fionda, Cinzia
Zingoni, Alessandra
Soriani, Alessandra
Petrucci, Maria Teresa
Ricciardi, Maria Rosaria
Molfetta, Rosa
Paolini, Rossella
Santoni, Angela
Cippitelll, Marco
CELL DEATH & DISEASE, 2019, 10 (4)
[6] The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors
Maria Pia Abruzzese
Maria Teresa Bilotta
Cinzia Fionda
Alessandra Zingoni
Alessandra Soriani
Maria Teresa Petrucci
Maria Rosaria Ricciardi
Rosa Molfetta
Rossella Paolini
Angela Santoni
Marco Cippitelli
Cell Death & Disease, 10
[7] PIM1-Mediated CXCR4 Phosphorylation: A Potentially Class-Distinct Therapeutic Target of Next Generation Proteasome Inhibitors in Multiple Myeloma
Waldschmidt, Johannes M.
Wider, Dagmar
Mueller, Stefan J.
Simon, Anna
Decker, Sarah
Follo, Marie
Duyster, Justus
Waesch, Ralph
Engelhardt, Monika
BLOOD, 2016, 128 (22)

← 1 →